Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Waters (WAT – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Merck & Company (MRK)
In a report released yesterday, Asad Haider from Goldman Sachs maintained a Buy rating on Merck & Company, with a price target of $120.00. The company’s shares closed last Monday at $107.40.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $118.35, a 9.8% upside from current levels. In a report issued on January 16, Wells Fargo also maintained a Buy rating on the stock with a $125.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Waters (WAT)
In a report released today, Sidharth Sahoo from HSBC initiated coverage with a Buy rating on Waters and a price target of $460.00. The company’s shares closed last Monday at $390.90.
According to TipRanks.com, Sahoo is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Waters with a $423.80 average price target, an 8.2% upside from current levels. In a report issued on January 13, TipRanks – DeepSeek also upgraded the stock to Buy with a $442.00 price target.
